Physician profile
Jason A Berner
NPI 1144201781
$457,106.53
in general payments reported to CMS, 2019-2025
69 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $171K · 2020: $65K · 2021: $29K · 2022: $74K · 2023: $47K · 2024: $47K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Food and Beverage: $10K · Travel and Lodging: $9,807 · Honoraria: $600 · Consulting Fee: $300 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,518.75 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,533.50 |
| Food and Beverage | $10,241.57 |
| Travel and Lodging | $9,807.27 |
| Honoraria | $600.00 |
| Consulting Fee | $300.00 |
| Education | $231.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $291,788.61 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $32,626.41 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $29,356.08 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27,139.79 | 2019-2025 | Jardiance |
| Dexcom, INC. | $22,758.76 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Abbott Laboratories | $22,148.50 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $6,914.44 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $4,719.40 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $2,568.61 | 2019-2020 | |
| Novo Nordisk INC | $2,124.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Ibsa Pharma INC. | $2,094.13 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $1,737.12 | 2019-2024 | Unithroid |
| Corcept Therapeutics | $1,322.48 | 2019-2025 | Korlym |
| Mannkind Corporation | $905.70 | 2019-2025 | Afrezza |
| Insulet Corporation | $826.41 | 2019-2025 | Omnipod |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $806.39 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $707.89 | 2019-2025 | Tepezza, Repatha, Repatha |
| Bigfoot Biomedical INC | $609.76 | 2022 | |
| Merck Sharp & Dohme LLC | $555.22 | 2019-2025 | |
| Antares Pharma, INC. | $475.64 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Tandem Diabetes Care, INC. | $447.47 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $409.77 | 2021-2023 | |
| Medtronic, INC. | $371.96 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Cequr Corporation | $326.04 | 2021-2025 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $292.42 | 2025 | Yorvipath |
| Valeritas, INC. | $286.31 | 2019 | |
| Zealand Pharma US, INC. | $237.79 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $174.46 | 2022-2024 | Strensiq |
| Medtronic Minimed, INC. | $167.32 | 2019-2020 | |
| Metuchen Pharmaceuticals | $166.67 | 2019 | |
| Horizon Therapeutics Plc | $163.39 | 2023 | Tepezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.01 | 2019-2023 | Cycloset |
| Kyowa Kirin, INC. | $139.34 | 2023-2025 | Crysvita |
| Pfizer INC. | $136.87 | 2019-2023 | |
| Intuity Medical INC | $128.03 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Esperion Therapeutics, INC. | $127.02 | 2021-2025 | Nexletol |
| Astellas Pharma US INC | $99.00 | 2024 | |
| Madrigal Pharmaceuticals | $91.90 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $89.32 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Takeda Pharmaceuticals U.S.A., INC. | $77.65 | 2020-2021 | |
| Verity Pharmaceuticals INC. | $77.63 | 2024-2025 | Tlando |
| Sequel Med Tech, LLC | $64.99 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $64.12 | 2020-2022 | |
| Embecta Corp. | $62.59 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Neurocrine Biosciences, INC. | $61.64 | 2025 | |
| Recordati_rare_diseases_inc. | $48.12 | 2021-2024 | Signifor Lar, Isturisa |
| Endo Pharmaceuticals INC. | $46.89 | 2020-2021 | |
| Senseonics, Incorporated | $44.00 | 2019 | |
| Radius Health, INC. | $41.84 | 2023-2025 | Tymlos |
| Shire North American Group INC | $40.96 | 2019 | |
| Halozyme INC | $39.44 | 2023 | |
| Averitas Pharma INC. | $28.13 | 2024 | Qutenza |
| Tolmar, INC. | $19.84 | 2023 | |
| Eisai INC. | $19.65 | 2023 | |
| Ascensia Diabetes Care US INC. | $18.66 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.35 | 2025 | |
| Organon LLC | $18.04 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.44 | 2020 | |
| Roche Diabetes Care, INC. | $16.77 | 2020 | |
| Acella Pharmaceuticals, LLC | $16.52 | 2025 | NP Thyroid 60 |
| Amryt Pharma Holdings Ltd | $16.47 | 2022 | |
| Currax Pharmaceuticals LLC | $16.20 | 2021 | |
| Eusa Pharma (US) LLC | $11.65 | 2022 | |
| Acerus Pharmaceuticals Corporation | $11.50 | 2021 | |
| Echosens North America, INC. | $8.45 | 2025 | Fibroscan |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$27,786.91 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Berner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.